These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

880 related articles for article (PubMed ID: 31828683)

  • 1. Non-alcoholic fatty liver diseases: from role of gut microbiota to microbial-based therapies.
    Ebrahimzadeh Leylabadlo H; Ghotaslou R; Samadi Kafil H; Feizabadi MM; Moaddab SY; Farajnia S; Sheykhsaran E; Sanaie S; Shanehbandi D; Bannazadeh Baghi H
    Eur J Clin Microbiol Infect Dis; 2020 Apr; 39(4):613-627. PubMed ID: 31828683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease.
    Koopman N; Molinaro A; Nieuwdorp M; Holleboom AG
    Aliment Pharmacol Ther; 2019 Sep; 50(6):628-639. PubMed ID: 31373710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease.
    Suk KT; Kim DJ
    Expert Rev Gastroenterol Hepatol; 2019 Mar; 13(3):193-204. PubMed ID: 30791767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Probiotics in Non-alcoholic Fatty Liver Disease: Does Gut Microbiota Matter?
    Xie C; Halegoua-DeMarzio D
    Nutrients; 2019 Nov; 11(11):. PubMed ID: 31752378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanistic and physiological approaches of fecal microbiota transplantation in the management of NAFLD.
    Gupta M; Krishan P; Kaur A; Arora S; Trehanpati N; Singh TG; Bedi O
    Inflamm Res; 2021 Jul; 70(7):765-776. PubMed ID: 34212214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microbiota-Associated Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Cancer: A Review.
    Chen YH; Wu WK; Wu MS
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32825440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives.
    Hu H; Lin A; Kong M; Yao X; Yin M; Xia H; Ma J; Liu H
    J Gastroenterol; 2020 Feb; 55(2):142-158. PubMed ID: 31845054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fighting Fatty Liver Diseases with Nutritional Interventions, Probiotics, Symbiotics, and Fecal Microbiota Transplantation (FMT).
    Nobili V; Mosca A; Alterio T; Cardile S; Putignani L
    Adv Exp Med Biol; 2019; 1125():85-100. PubMed ID: 30578461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic advances in non-alcoholic fatty liver disease: A microbiota-centered view.
    Chen HT; Huang HL; Li YQ; Xu HM; Zhou YJ
    World J Gastroenterol; 2020 Apr; 26(16):1901-1911. PubMed ID: 32390701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of gut microbiome in nonalcoholic fatty liver disease: pro-, pre-, syn-, and antibiotics.
    Cho MS; Kim SY; Suk KT; Kim BY
    J Microbiol; 2018 Dec; 56(12):855-867. PubMed ID: 30377993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives.
    Vallianou N; Christodoulatos GS; Karampela I; Tsilingiris D; Magkos F; Stratigou T; Kounatidis D; Dalamaga M
    Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanistic and therapeutic advances in non-alcoholic fatty liver disease by targeting the gut microbiota.
    Han R; Ma J; Li H
    Front Med; 2018 Dec; 12(6):645-657. PubMed ID: 30178233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD).
    Safari Z; Gérard P
    Cell Mol Life Sci; 2019 Apr; 76(8):1541-1558. PubMed ID: 30683985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gut microbiome and non-alcoholic fatty liver disease.
    Purohit A; Alam MJ; Kandiyal B; Shalimar ; Das B; Banerjee SK
    Prog Mol Biol Transl Sci; 2022; 191(1):187-206. PubMed ID: 36270678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-alcoholic fatty liver disease and gut microbial dysbiosis- underlying mechanisms and gut microbiota mediated treatment strategies.
    Jayachandran M; Qu S
    Rev Endocr Metab Disord; 2023 Dec; 24(6):1189-1204. PubMed ID: 37840104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fecal microbiota transplantation: a promising strategy in preventing the progression of non-alcoholic steatohepatitis and improving the anti-cancer immune response.
    Delaune V; Orci LA; Lacotte S; Peloso A; Schrenzel J; Lazarevic V; Toso C
    Expert Opin Biol Ther; 2018 Oct; 18(10):1061-1071. PubMed ID: 30173562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The intestinal microbiota as a therapeutic target in the treatment of NAFLD and ALD.
    Huang W; Kong D
    Biomed Pharmacother; 2021 Mar; 135():111235. PubMed ID: 33561650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease.
    Woodhouse CA; Patel VC; Singanayagam A; Shawcross DL
    Aliment Pharmacol Ther; 2018 Jan; 47(2):192-202. PubMed ID: 29083037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting nonalcoholic fatty liver disease via gut microbiome-centered therapies.
    Koning M; Herrema H; Nieuwdorp M; Meijnikman AS
    Gut Microbes; 2023; 15(1):2226922. PubMed ID: 37610978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Effects of Probiotics, Prebiotics and Synbiotics in Non-Alcoholic Fat Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH): A Systematic Review.
    Carpi RZ; Barbalho SM; Sloan KP; Laurindo LF; Gonzaga HF; Grippa PC; Zutin TLM; Girio RJS; Repetti CSF; Detregiachi CRP; Bueno PCS; Mazuqueli Pereira ESB; Goulart RA; Haber JFDS
    Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.